MCM2在直肠癌的表达及其预后意义

MCM2 expression in rectal cancer and its prognostic significance

目的探讨MCM2在直肠癌的表达及其预后意义。方法采用免疫组织化学方法检测MCM2在70例直肠癌标本中的表达,计算其表达标记指数,并将其分成4组:0～25%,26%～50%,51%～75%和76%～100%;同时分析MCM2表达与临床病理之间的关系,再采用Cox比例风险模型分析MCM2是否为一独立的预后指标。结果70例直肠癌标本均表达MCM2,且其表达与肿瘤的分化程度有显著相关性(P<0.001),而于Dukes分期无显著相关性。Cox比例风险模型分析显示各组病人的相对生存危险度(RR)分别为1.0(参照)、5.61、13.57,三者间差异有有显著意义(P<0.05)。结论MCM2可能是直肠癌一新的增值标记物,其表达标记指数是直肠癌的独立预后指标。

Objective: To investigate MCM2 expression and study the prognostic utility of MCM2 on survival of patients with rectal cancer. Methods: We examined the immunohistochemical expression of MCM2 in tumor specimens from 70 patients with rectal cancer. The labelling index was assessed and categorized into four groups: 0% to 25%, 26% to 50%, 51% to 75% and 76% to 100%. An analysis of the association between MCM2 expression and clinicopathological characteristics of rectal cancer was carried out. Cox proportional hazard analysis was performed to determine whether MCM2 staining was a significant independent predictor of survival or not. Results: MCM2 was expressed in all 70 rectal cancer specimens, and a significant association was demonstrated between MCM2 expression and the degree of tumor differentiation (P<0.001). But there was no significant association between MCM2 expression and Dukes stage. Cox proportional hazard analysis indicated that the relative risk (RR) of three groups were 1.0 (reference), 5.61 and 13.57 resperctively, and the differences among the three groups were significant(P<0.05). Conclusions: MCM2 may serve as a novel proliferation marker in rectal cancer. Immunostaining of tumor cells for MCM2 is an independent prognostic parameter of survival for patients with rectal cancer.